Opportunities Preloader

Please Wait.....

Report

Preclinical CRO Market Forecast till 2030

Market Report I 2023-04-26 I 125 Pages I Market Research Future
Discounted by 20% to 2024-03-31

Preclinical CRO Market Forecast till 2030
Market Overview
The growth of the preclinical CRO market is expanding due to the R&D activities in the pharmaceutical and biotechnology sectors. As the demand for new drugs and therapies increases, pharmaceutical and biotech companies are allocating larger budgets for R&D to accelerate the drug development process. This includes outsourcing preclinical research activities to CROs, which offer specialized services and expertise in conducting preclinical studies to evaluate the safety and efficacy of new drug candidates.
Moreover, preclinical CROs provide cost-effective and time-efficient solutions for drug development compared to in-house research, as they offer access to state-of-the-art facilities, equipment, and expertise without the need for substantial investment in infrastructure and personnel. This cost-effective approach is especially appealing to smaller biotech companies and startups with limited resources, driving the demand for preclinical CRO services.
The demand for preclinical trials involving large molecules has also increased, and there is a need to reduce R&D expenses. Although the ongoing COVID-19 pandemic initially disrupted preclinical research projects, the development of lifesaving drugs has continued at a rapid pace. Additionally, the need to combat the spread of new viruses and infections and notable R&D initiatives in the healthcare sector is driving the market, globally. This industry's potential is also expected to increase due to the expected rise in the number of novel drugs entering the preclinical phase. Moreover, several pharmaceuticals and biotechnology companies are outsourcing preclinical validation programs to address medical needs, creating profitable opportunities for the market.
Segment Overview
he toxicology testing segment is expected to continue leading the growth in the preclinical CRO market, driven by the increasing demand for new drugs and chemicals. As drug development efforts continue to expand, toxicology testing plays a crucial role in evaluating the safety and potential adverse effects of new compounds, which is essential for regulatory approvals.
Additionally, the bioanalysis and DMPK segment is anticipated to grow in CAGR, as these services are essential for understanding the drug's metabolism, pharmacokinetics, and bioavailability. This information is critical in optimizing drug dosing regimens and ensuring their effectiveness in humans.
Moreover, oncology is expected to become the top segment in the near future, as cancer remains a significant global health challenge, and there is a high demand for novel oncology therapies. The increasing focus on precision medicine and targeted therapies for cancer treatment is driving the need for preclinical studies in oncology.
Furthermore, the pharmaceutical and biopharmaceutical sectors are predicted to be the key drivers of future growth in the preclinical CRO market. These sectors continue to invest in R&D to develop new drugs and therapies, and outsourcing preclinical studies to CROs allows them to streamline their drug development processes, reduce costs, and accelerate timelines.
Regional Analysis
North American region holds the biggest share of the preclinical CRO market as of 2021, mainly due to the presence of established CROs such as Charles River Laboratories and LabCorp that specialize in early drug discovery. The United States leads in outsourcing preclinical trials as many biopharmaceutical companies prefer to take advantage of the Investigational New Drug (IND) application approved by the FDA.
In the coming years, the Asia Pacific is expected to grow fastest growth in the preclinical CRO market due to changing business models of multinational corporations (MNCs) outsourcing and the increasing cost of research and development. The region is cost-efficient for outsourcing as it offers CROs located in countries such as India and China. Western European and U.S. based companies are also outsourcing analytical services, site research development, and clinical activities to the Asia Pacific region to reduce research-related costs.
Major Player
Envigo (U.S.), Eurofins Scientific (Luxembourg), Medpace (U.S.), Laboratory Corporation of America Holdings (U.S.), PRA Health Sciences (U.S.), D. Biosciences (U.S.), Charles River (U.S.), WuXi AppTec (China), and ICON PLC (Dublin), Pharmaceutical Product Development, LLC (U.S.), PAREXEL International Corporation (U.S.), IQVIA (U.S.) are among the companies operating in this market.
COVID 19, Impacts
The development of a COVID-19 vaccine and therapeutic treatments has led to a surge in demand for preclinical research services in this area, ongoing research projects have faced disruptions and delays due to compliance with social distancing regulations and temporary closures of research facilities and laboratories. Moreover, the economic uncertainty caused by the pandemic has resulted in reduced funding for some preclinical research projects, leading to a decline in demand for CRO services in certain sectors. However, demand for preclinical research in fields such as oncology, neurology, and cardiology has remained steady. In response to these challenges, the preclinical CRO market has embraced digital tools and virtual services, with remote monitoring, telemedicine, and virtual clinical trials becoming more common. This shift to digital platforms has enabled preclinical research to continue even amidst restrictions on physical laboratory access.

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 MARKET STRUCTURE 16
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 17
3.2 PRIMARY RESEARCH 18
3.3 SECONDARY RESEARCH 18
3.4 MARKET SIZE ESTIMATION 19
3.5 FORECAST MODEL 20
4 MARKET DYNAMICS
4.1 OVERVIEW 21
4.2 DRIVERS 22
4.2.1 GROWTH IN OUTSOURCING OF NON-CORE FUNCTIONS 22
4.2.2 ENHANCED ABILITIES OF PRECLINICAL CROS TO OFFER ADDITIONAL VALUE-ADDED SERVICES 22
4.2.3 SURGING NUMBER OF DRUGS IN THE PRECLINICAL PHASE 22
4.2.4 ECONOMIES OF PRODUCTION AND SCALE 22
4.2.5 MUTUAL BENEFIT TO THE CONTRACTOR AS WELL AS THE CLIENT 22
4.2.6 HIGH R&D EXPENDITURE 23
4.3 RESTRAINTS 24
4.3.1 SCARCITY OF LABOUR AND HIGH LABOUR COST 24
4.3.2 STRUCTURAL CHANGES IN THE INDUSTRY 24
4.4 OPPORTUNITY 24
4.4.1 OPPORTUNITY FOR MEDICAL DEVICE COMPANIES TO OUTSOURCE PRECLINICAL TRIALS TO CROS 24
4.5 CHALLENGES 25
4.5.1 SUPPLY CHAIN COMPLEXITY AND THIRD-PARTY CONTROL 25
4.5.2 OUTDATED CLINICAL TRIAL ACTIVITIES 25
4.6 MACROECONOMIC INDICATORS 25
4.7 TRENDS 25
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 26
5.1.1 R&D 26
5.1.2 GOOD LABORATORY PRACTICES (GLP) 26
5.1.3 PRE-CLINICAL CRO TESTING 26
5.2 PORTER'S FIVE FORCES ANALYSIS 27
5.2.1 BARGAINING POWER OF SUPPLIERS 27
5.2.2 BARGAINING POWER OF BUYERS 27
5.2.3 THREAT OF NEW ENTRANTS 28
5.2.4 THREAT OF SUBSTITUTES 28
5.2.5 INTENSITY OF RIVALRY 28
5.3 INVESTMENT OPPORTUNITIES 28
5.4 PRICING ANALYSIS 28
6 PRECLINICAL CRO MARKET, BY SERVICE
6.1 OVERVIEW 29
6.2 TOXICOLOGY TESTING 31
6.3 BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES 32
6.4 OTHERS 33
7 PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
7.1 OVERVIEW 34
7.2 ONCOLOGY 36
7.3 CENTRAL NERVOUS SYSTEM (CNS) DISORDERS 37
7.4 CARDIOVASCULAR DISEASES 38
7.5 IMMUNOLOGICAL DISORDERS 39
7.6 RESPIRATORY DISEASES 40
7.7 INFECTIOUS DISEASES 41
7.8 DIABETES 42
7.9 OTHERS 43
8 PRECLINICAL CRO MARKET, BY END USER
8.1 OVERVIEW 44
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL INDUSTRIES 46
8.3 MEDICAL DEVICE COMPANIES 47
8.4 ACADEMIC INSTITUTES 48
9 GLOBAL PRECLINICAL CRO MARKET, BY REGION
9.1 OVERVIEW 49
9.2 AMERICAS 51
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.2.1 NORTH AMERICA 53
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.2.1.1 US 56
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.2.1.2 CANADA 57
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.2.2 LATIN AMERICA 59
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3 EUROPE 61
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1 WESTERN EUROPE 63
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.1 GERMANY 66
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.2 FRANCE 67
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.3 UK 69
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.4 ITALY 70
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.5 SPAIN 72
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.1.6 REST OF WESTERN EUROPE 73
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.3.2 EASTERN EUROPE 75
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4 ASIA-PACIFIC 77
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.1 JAPAN 80
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.2 CHINA 81
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.3 INDIA 83
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.4 AUSTRALIA 84
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.5 SOUTH KOREA 86
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 87
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 89
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.5.1 MIDDLE EAST 91
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
9.5.2 AFRICA 93
PRECLINICAL CRO MARKET, BY SERVICE
PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA
PRECLINICAL CRO MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION 95
10.2 COMPANY SHARE ANALYSIS 95
11 COMPANY PROFILE
11.1 IQVIA 99
11.1.1 COMPANY OVERVIEW 99
11.1.2 FINANCIAL OVERVIEW 99
11.1.3 PRODUCTS/SERVICES OFFERED 100
11.1.4 KEY DEVELOPMENTS 100
11.1.5 SWOT ANALYSIS 101
11.1.6 KEY STRATEGIES 101
11.2 PAREXEL INTERNATIONAL CORPORATION 102
11.2.1 COMPANY OVERVIEW 102
11.2.2 FINANCIAL OVERVIEW 102
11.2.3 PRODUCTS OFFERING 103
11.2.4 KEY DEVELOPMENTS 103
11.2.5 SWOT ANALYSIS 103
11.2.6 KEY STRATEGIES 103
11.3 ENVIGO 104
11.3.1 COMPANY OVERVIEW 104
11.3.2 FINANCIAL OVERVIEW 104
11.3.3 PRODUCTS OFFERING 104
11.3.4 KEY DEVELOPMENTS 104
11.3.5 SWOT ANALYSIS 105
11.3.6 KEY STRATEGIES 105
11.4 CHARLES RIVER 106
11.4.1 COMPANY OVERVIEW 106
11.4.2 FINANCIAL OVERVIEW 106
11.4.3 PRODUCTS/SERVICES OFFERED 106
11.4.4 KEY DEVELOPMENTS 107
11.4.5 SWOT ANALYSIS 107
11.4.6 KEY STRATEGIES 107
11.5 EUROFINS SCIENTIFIC 108
11.5.1 COMPANY OVERVIEW 108
11.5.2 FINANCIAL OVERVIEW 108
11.5.3 PRODUCTS/SERVICES OFFERED 108
11.5.4 KEY DEVELOPMENTS 109
11.5.5 SWOT ANALYSIS 109
11.5.6 KEY STRATEGIES 109
11.6 ICON PLC 110
11.6.1 COMPANY OVERVIEW 110
11.6.2 FINANCIAL OVERVIEW 110
11.6.3 PRODUCTS/SERVICES OFFERED 110
11.6.4 KEY DEVELOPMENTS 111
11.6.5 SWOT ANALYSIS 111
11.6.6 KEY STRATEGIES 111
11.7 PRA HEALTH SCIENCES (PRA) 112
11.7.1 COMPANY OVERVIEW 112
11.7.2 FINANCIAL OVERVIEW 112
11.7.3 PRODUCTS/SERVICES OFFERED 112
11.7.4 KEY DEVELOPMENTS 113
11.7.5 SWOT ANALYSIS 113
11.7.6 KEY STRATEGIES 113
11.8 MEDPACE 114
11.8.1 COMPANY OVERVIEW 114
11.8.2 FINANCIAL OVERVIEW 114
11.8.3 PRODUCTS/SERVICES OFFERED 114
11.8.4 KEY DEVELOPMENTS 115
11.8.5 SWOT ANALYSIS 115
11.8.6 KEY STRATEGIES 115
11.9 LABORATORY CORPORATION OF AMERICA HOLDINGS 116
11.9.1 COMPANY OVERVIEW 116
11.9.2 FINANCIAL OVERVIEW 116
11.9.3 PRODUCTS/SERVICES OFFERED 117
11.9.4 KEY DEVELOPMENTS 117
11.9.5 SWOT ANALYSIS 117
11.9.6 KEY STRATEGIES 117
11.10 PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC 118
11.10.1 COMPANY OVERVIEW 118
11.10.2 FINANCIAL OVERVIEW 118
11.10.3 PRODUCTS/SERVICES OFFERED 118
11.10.4 KEY DEVELOPMENTS 118
11.10.5 SWOT ANALYSIS 118
11.10.6 KEY STRATEGIES 119
11.11 WUXI APPTEC 120
11.11.1 COMPANY OVERVIEW 120
11.11.2 FINANCIAL OVERVIEW 120
11.11.3 PRODUCTS/SERVICES OFFERED 120
11.11.4 KEY DEVELOPMENTS 120
11.11.5 SWOT ANALYSIS 121
11.11.6 KEY STRATEGIES 121
11.12 MD BIOSCIENCES 122
11.12.1 COMPANY OVERVIEW 122
11.12.2 FINANCIAL OVERVIEW 122
11.12.3 PRODUCTS/SERVICES OFFERED 122
11.12.4 KEY DEVELOPMENTS 122
11.12.5 SWOT ANALYSIS 122
11.12.6 KEY STRATEGIES 123
12 APPENDIX
12.1 REFERENCES 124
12.2 RELATED REPORTS 124

LIST OF TABLES
TABLE 1 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 29
TABLE 2 GLOBAL PRECLINICAL CRO MARKET, FOR TOXICOLOGY TESTING, BY REGION, 2022-2030 (USD MILLION) 31
TABLE 3 GLOBAL PRECLINICAL CRO MARKET, FOR BIOANALYSIS AND DRUG METABOLISM AND PHARMACOKINETICS (DMPK) STUDIES, BY REGION, 2022-2030 (USD MILLION) 32
TABLE 4 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 33
TABLE 5 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 34
TABLE 6 GLOBAL PRECLINICAL CRO MARKET, FOR ONCOLOGY, BY REGION, 2022-2030 (USD MILLION) 36
TABLE 7 GLOBAL PRECLINICAL CRO MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, BY REGION, 2022-2030 (USD MILLION) 37
TABLE 8 GLOBAL PRECLINICAL CRO MARKET, FOR CARDIOVASCULAR DISEASES, BY REGION, 2022-2030 (USD MILLION) 38
TABLE 9 GLOBAL PRECLINICAL CRO MARKET, FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2022-2030 (USD MILLION) 39
TABLE 10 GLOBAL PRECLINICAL CRO MARKET, FOR RESPIRATORY DISEASES, BY REGION, 2022-2030 (USD MILLION) 40
TABLE 11 GLOBAL PRECLINICAL CRO MARKET, FOR INFECTIOUS DISEASES, BY REGION, 2022-2030 (USD MILLION) 41
TABLE 12 GLOBAL PRECLINICAL CRO MARKET, FOR DIABETES, BY REGION, 2022-2030 (USD MILLION) 42
TABLE 13 GLOBAL PRECLINICAL CRO MARKET, FOR OTHERS, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 14 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 44
TABLE 15 GLOBAL PRECLINICAL CRO MARKET, FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRIES, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 16 GLOBAL PRECLINICAL CRO MARKET, FOR MEDICAL DEVICE COMPANIES, BY REGION, 2022-2030 (USD MILLION) 47
TABLE 17 GLOBAL PRECLINICAL CRO MARKET, FOR ACADEMIC INSTITUTES, BY REGION, 2022-2030 (USD MILLION) 48
TABLE 18 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 49
TABLE 19 GLOBAL PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 50
TABLE 20 GLOBAL PRECLINICAL CRO MARKET, BY REGION, 2022 & 2030 (USD MILLION) 50
TABLE 21 AMERICAS: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 51
TABLE 22 AMERICAS: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 52
TABLE 23 AMERICAS: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 52
TABLE 24 AMERICAS: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 53
TABLE 25 NORTH AMERICA: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 53
TABLE 26 NORTH AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 54
TABLE 27 NORTH AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 55
TABLE 28 NORTH AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 55
TABLE 29 US: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 56
TABLE 30 US: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 56
TABLE 31 US: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 57
TABLE 32 CANADA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 57
TABLE 33 CANADA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 58
TABLE 34 CANADA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 58
TABLE 35 LATIN AMERICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 59
TABLE 36 LATIN AMERICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 59
TABLE 37 LATIN AMERICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 60
TABLE 38 EUROPE: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 61
TABLE 39 EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 62
TABLE 40 EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 62
TABLE 41 EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 63
TABLE 42 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 63
TABLE 43 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 64
TABLE 44 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 65
TABLE 45 WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 65
TABLE 46 GERMANY: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 66
TABLE 47 GERMANY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 66
TABLE 48 GERMANY: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 67
TABLE 49 FRANCE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 67
TABLE 50 FRANCE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 68
TABLE 51 FRANCE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 68
TABLE 52 UK: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 69
TABLE 53 UK: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 69
TABLE 54 UK: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 70
TABLE 55 ITALY: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 70
TABLE 56 ITALY: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 71
TABLE 57 ITALY: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 71
TABLE 58 SPAIN: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 72
TABLE 59 SPAIN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 72
TABLE 60 SPAIN: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 73
TABLE 61 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 73
TABLE 62 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 74
TABLE 63 REST OF WESTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 74
TABLE 64 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 75
TABLE 65 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 75
TABLE 66 EASTERN EUROPE: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 76
TABLE 67 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 77
TABLE 68 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 78
TABLE 69 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 79
TABLE 70 ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 79
TABLE 71 JAPAN: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 80
TABLE 72 JAPAN: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 80
TABLE 73 JAPAN: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 81
TABLE 74 CHINA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 81
TABLE 75 CHINA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 82
TABLE 76 CHINA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 82
TABLE 77 INDIA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 83
TABLE 78 INDIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 83
TABLE 79 INDIA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 84
TABLE 80 AUSTRALIA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 84
TABLE 81 AUSTRALIA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 85
TABLE 82 AUSTRALIA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 85
TABLE 83 SOUTH KOREA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 86
TABLE 84 SOUTH KOREA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 86
TABLE 85 SOUTH KOREA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 87
TABLE 86 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 87
TABLE 87 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 88
TABLE 88 REST OF ASIA-PACIFIC: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 88
TABLE 89 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY REGION, 2022-2030 (USD MILLION) 89
TABLE 90 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 90
TABLE 91 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 90
TABLE 92 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 91
TABLE 93 MIDDLE EAST: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 91
TABLE 94 MIDDLE EAST: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 92
TABLE 95 MIDDLE EAST: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 92
TABLE 96 AFRICA: PRECLINICAL CRO MARKET, BY SERVICE, 2022-2030 (USD MILLION) 93
TABLE 97 AFRICA: PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022-2030 (USD MILLION) 93
TABLE 98 AFRICA: PRECLINICAL CRO MARKET, BY END USER, 2022-2030 (USD MILLION) 94
TABLE 99 KEY DEVELOPMENTS & STRATEGIES 96

LIST OF FIGURES
FIGURE 1 MARKET SYNOPSIS 15
FIGURE 2 GLOBAL PRECLINICAL CRO MARKET: MARKET STRUCTURE 16
FIGURE 3 RESEARCH PROCESS OF MRFR 17
FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH 20
FIGURE 5 MARKET DYNAMICS: GLOBAL PRECLINICAL CRO MARKET 21
FIGURE 6 VALUE CHAIN: GLOBAL PRECLINICAL CRO MARKET 26
FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PRECLINICAL CRO MARKET 27
FIGURE 8 GLOBAL PRECLINICAL CRO MARKET SHARE, BY SERVICE, 2022 (%) 30
FIGURE 9 GLOBAL PRECLINICAL CRO MARKET, BY SERVICE, 2022 & 2030 (USD MILLION) 30
FIGURE 10 GLOBAL PRECLINICAL CRO MARKET SHARE, BY THERAPEUTIC AREA, 2022 (%) 35
FIGURE 11 GLOBAL PRECLINICAL CRO MARKET, BY THERAPEUTIC AREA, 2022 & 2030 (USD MILLION) 35
FIGURE 12 GLOBAL PRECLINICAL CRO MARKET SHARE, BY END USER, 2022 (%) 45
FIGURE 13 GLOBAL PRECLINICAL CRO MARKET, BY END USER, 2022 & 2030 (USD MILLION) 45
FIGURE 14 AMERICAS: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 51
FIGURE 15 NORTH AMERICA: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 54
FIGURE 16 EUROPE: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 61
FIGURE 17 WESTERN EUROPE: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 64
FIGURE 18 ASIA-PACIFIC: PRECLINICAL CRO MARKET SHARE, BY COUNTRY, 2022 (%) 78
FIGURE 19 MIDDLE EAST & AFRICA: PRECLINICAL CRO MARKET SHARE, BY REGION, 2022 (%) 89
FIGURE 20 GLOBAL PRECLINICAL CRO MARKET SHARE ANALYSIS 2022 (%) 95

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE